1834 Investment Advisors Co. Has $8.97 Million Stock Position in Pfizer Inc. (NYSE:PFE)

1834 Investment Advisors Co. cut its holdings in Pfizer Inc. (NYSE:PFE) by 2.0% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 309,885 shares of the biopharmaceutical company’s stock after selling 6,247 shares during the quarter. Pfizer accounts for 1.0% of 1834 Investment Advisors Co.’s investment portfolio, making the stock its 23rd largest holding. 1834 Investment Advisors Co.’s holdings in Pfizer were worth $8,968,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of PFE. China Universal Asset Management Co. Ltd. acquired a new stake in Pfizer in the first quarter valued at approximately $315,000. Central Pacific Bank Trust Division bought a new stake in Pfizer during the 1st quarter valued at $136,000. GSA Capital Partners LLP acquired a new position in Pfizer during the first quarter worth $439,000. Disciplined Equity Management Inc. lifted its stake in shares of Pfizer by 2,676.8% in the first quarter. Disciplined Equity Management Inc. now owns 66,920 shares of the biopharmaceutical company’s stock valued at $1,857,000 after buying an additional 64,510 shares in the last quarter. Finally, Broderick Brian C grew its holdings in shares of Pfizer by 382.9% during the first quarter. Broderick Brian C now owns 34,550 shares of the biopharmaceutical company’s stock valued at $959,000 after buying an additional 27,396 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insider Transactions at Pfizer

In other news, Director Scott Gottlieb acquired 1,000 shares of the stock in a transaction that occurred on Wednesday, October 30th. The shares were acquired at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the purchase, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. The trade was a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.06% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages recently weighed in on PFE. Wells Fargo & Company raised their price target on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Wednesday, October 23rd. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Citigroup initiated coverage on Pfizer in a research note on Friday, October 25th. They set a “neutral” rating and a $30.00 price objective on the stock. Finally, StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. Eight investment analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $33.58.

Pfizer Price Performance

PFE opened at $27.98 on Wednesday. The firm has a market cap of $158.55 billion, a P/E ratio of 37.81, a PEG ratio of 0.89 and a beta of 0.67. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $31.54. The firm has a 50-day moving average of $28.99 and a 200 day moving average of $28.65.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.40%. The company’s revenue was up 31.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.17) EPS. On average, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.00%. Pfizer’s dividend payout ratio is presently 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.